Another question I can’t answer. Again, NP blocked the paper over a disagreement on ownership of the data. As to why he did that and how ownership of the data would benefit CYDY, I’m not exactly sure and can only speculate at this point. This ultimately may have zero impact on leronlimab, but it does highlight additional issues with a CEO who has already made questionable decisions.

I think a simple solution would be for Dr. BP to resubmit the data to a journal without NP’s name as a contributor because he didn’t scientifically contribute to the findings. Yes, he’s the CEO of the company who provided the medication to the patient, but he did not personally test the patient, analyze the labs, or review the data.